Want to see SE:BICO full AI Analyst Report?
BICO Stock Chart & Stats
kr19.92
kr0.92(6.88%)
At close: 4:00 PM EDT
kr19.92
kr0.92(6.88%)
Day’s Range― - ―
52-Week Rangekr12.94 - kr25.42
Previous CloseN/A
Volume297.54K
Average Volume (3M)259.05K
Market Cap
kr1.58B
Enterprise Valuekr1.20B
Total Cash (Recent Filing)kr627.60M
Total Debt (Recent Filing)kr266.40M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 11, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.89
Shares Outstanding69,074,900
10 Day Avg. Volume174,504
30 Day Avg. Volume259,049
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.99
P/FCF Ratio26.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.39
Revenue Forecast (FY)kr1.62B
Bulls Say, Bears Say
Bulls Say
Margin ImprovementThe sharp improvement in gross margin and adjusted EBITDA indicates that pricing, product mix, and operating discipline are improving the earnings model. If sustained, these gains can strengthen the company’s ability to convert revenue into internally funded growth and reduce dependence on external capital.
Long-term Contracted RevenueA decade-long supply and license agreement provides greater revenue visibility and demonstrates that BICO’s technologies can secure meaningful strategic commitments. The contract should support customer relationships, recurring commercial activity, and a more durable base for future life-science workflow adoption.
Stronger Balance SheetThe move to a net cash position materially improves financial flexibility compared with the prior net debt position. Greater liquidity can help BICO fund product development, absorb operating volatility, and pursue organic or selective bolt-on opportunities without immediately relying on additional leverage.
Bears Say
Deep Ongoing LossesBICO has not yet demonstrated a consistently profitable earnings model: the very negative net margin and operating losses show that revenue growth is still insufficient to cover the company’s cost base. Persistent losses can weaken capital efficiency and increase future dilution or refinancing risk.
Weak Cash ConversionNegative recent operating cash flow and free cash flow limit BICO’s ability to self-fund operations and investment, even as reported margins improve. Receivables, inventories, and lower payables created a material working-capital drag, making liquidity and cash conversion important ongoing execution challenges.
Project Execution And Demand RiskExecution problems in the U.S. project business and weaker end-market demand can make revenue recognition uneven and delay backlog conversion. Because large automation projects already have extended sales cycles, continued issues could pressure growth, resource allocation, and the durability of operating improvements.
BICO Group AB Class B News
BICO FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was kr12.94 and its highest was kr25.42 in the past 12 months.
What is BICO Group AB Class B’s market cap?
BICO Group AB Class B’s market cap is kr1.58B.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Nov 11, 2026 which is in 37 days.
How were BICO Group AB Class B’s earnings last quarter?
BICO Group AB Class B released its earnings results on Aug 19, 2026. The company reported -kr0.5 earnings per share for the quarter, beating the consensus estimate of -kr0.7 by kr0.2.
Is BICO Group AB Class B overvalued?
According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued.
Does BICO Group AB Class B pay dividends?
BICO Group AB Class B does not currently pay dividends.
What is BICO Group AB Class B’s EPS estimate?
BICO Group AB Class B’s EPS estimate is -0.15.
How many shares outstanding does BICO Group AB Class B have?
BICO Group AB Class B has 69,074,900 shares outstanding.
What happened to BICO Group AB Class B’s price movement after its last earnings report?
BICO Group AB Class B reported an EPS of -kr0.5 in its last earnings report, beating expectations of -kr0.7. Following the earnings report the stock price went up 13.189%.
Which hedge fund is a major shareholder of BICO Group AB Class B?
Currently, no hedge funds are holding shares in SE:BICO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BICO Group AB Class B
BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions division equips researchers with advanced tools like 3D bioprinters, hybrid microscopes, and instruments for single-cell dispensing and liquid handling. It also supplies essential consumables such as bioinks, reagents, microscope lenses, and specialized software, alongside 3D reconstructed human tissues crucial for regulatory testing. Furthermore, this segment provides specialized services in 3D cell culture, tissue imaging, multiplex imaging, and digital pathology, primarily benefiting pharmaceutical and biotechnology firms. Conversely, the Bioautomation segment caters to industrial clients with precision dispensing and biosensor technologies, while also delivering diagnostic automation and sophisticated robotics solutions to the medical and diagnostics sectors. Beyond these segments, BICO Group's comprehensive portfolio includes solutions for tissue engineering, multi-omics, cell line development, and diagnostics, contributing to a robust industrial ecosystem. Its principal clientele spans the medical, pharmaceutical, and cosmetic industries. Originally established in 2016 as Cellink AB (publ), the company adopted its current name, BICO Group AB (publ), in August 2021. Its headquarters are located in Gothenburg, Sweden.
BICO Company Deck
BICO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call combined meaningful operational and financial improvements (strong product launches, a large long-term license/supply agreement, substantial gross margin expansion, improved adjusted EBITDA margin, reductions in operating expenses and a stronger balance sheet) with persistent operational and market headwinds (project execution issues in the U.S. project business, negative operating cash flow driven by working capital movements, soft North American/academic end markets and longer sales cycles for large automation projects). Progress on commercialization and profitability is clear, but execution risk in project-based automation and short-term cash-flow/working-capital pressure leave mixed near-term visibility.View all SE:BICO earnings summariesTechnical Analysis
Vitrolife AB
―
BONESUPPORT HOLDING AB
―
CellaVision AB
―
Xvivo Perfusion AB
―
OssDsign AB
―